Close Menu

Memorial Sloan-Kettering

By testing 1,000 individuals with lung cancer for driver mutations in 10 genes, members of the Lung Cancer Mutation Consortium are finding mutations to help physicians offer more targeted treatment and clinical trial options for those with the disease.

An unusually high number of off-target effects obtained during a screen suggested that “misleading results in siRNA screens using large libraries with single-assay readout is substantial.”

A review of the National Cancer Institute's online clearinghouse for clinical trial information shows that more than a dozen groups worldwide are either conducting or preparing to launch studies examining miRNA signatures in humans with a variety of diseases.

Through a two-stage GWAS study, an international research team tracked down variants that modify the breast cancer risk associated with BRCA2 mutations, showing that these overlap with other breast cancer risk variants.

The licensing agreement pertains to a patent describing the diagnostic use of a fluorescent-based, allele-specific PCR assay to amplify the V600E mutation.

The company plans to use the BRAF-related IP in a PCR-based assay that could be used to help inform cancer treatment decisions.

The research team analyzed a combination of DNA sequence, copy number, and mRNA expression to identify several genes associated with soft-tissue sarcoma subtypes.

American researchers reported today they have identified microRNA-mediated interactions between coding and non-coding messenger RNAs.

The hospital believes it is the first to receive approval from the state to use the instrument for diagnosing gene mutations.


Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.